Key facts
- BlackRock, Inc. filed SCHEDULE 13G/A for SOLENO THERAPEUTICS INC Common Stock (SLNO).
- Disclosed ownership: 6.9%.
- Date of event: 31 Mar 2026.
BlackRock, Inc. - 31 Mar 2026 SCHEDULE 13G/A Report for SOLENO THERAPEUTICS INC Common Stock (SLNO)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Security
- SOLENO THERAPEUTICS INC Common Stock
- Symbol
- SLNO
- Shares outstanding
- 51,352,116 shares
- Disclosed Ownership
- 3,543,296 shares
- Ownership
- 6.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 24 Apr 2026, 16:11:56 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 17 Jul 2025
- SEC
- View on sec.gov
Key filing fact
BlackRock, Inc. disclosed 6.9% ownership in SOLENO THERAPEUTICS INC Common Stock (SLNO) on 31 Mar 2026.
Change
- Previous schedule filing date: 17 Jul 2025.
- Current filing was accepted on 24 Apr 2026, 16:11.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (1)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 6.9% | 3,543,296 | 3,471,113 | 0 | Spencer Fleming | Managing Director |
CIK / CUSIP context first